GNRH1 and prostate carcinoma: Androgens play a key function in the proliferation of androgen-sensitive prostate cancer [3], and androgen deprivation therapy is the gold standard treatment, either by using an agonist or an antagonist of gonadotropin-releasing hormone (GnRH) alone or an agonist of GnRH in combination with a pure antiandrogen [4–6].